Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1-2
|
pubmed:dateCreated |
1997-5-15
|
pubmed:abstractText |
Ewing's sarcoma family of tumors (EFT) contain reciprocal translocations, of which approximately 90% occur between the long arm of chromosomes 11 and 22,t(11;22)(q24;q12) resulting in the formation of chimeric proteins generated by a fusion of the EWS and FLI-1 genes. To determine if EWS-FLI-1 protein is responsible for the Ewing sarcoma phenotype we have used sequence-specific antisense oligodeoxynucleotides (ODN) to block its expression. We have evaluated a series of antisense ODN directed toward the breakpoint region in an effort to prevent translation of the fusion messenger RNA. ODN were first evaluated in a cell-free in vitro translation system. Exogenously added RNase H was found to be required for translation inhibition. ODN that showed complete inhibition of translation were electroporated into TC-32 cells, a EFT cell line. Fusion protein and EWS protein levels were evaluated by Western blot analysis. A 40-60% decrease in the fusion protein was observed in TC-32 cells with antisense ODN directed toward the breakpoint region. Cell viability was reduced with antisense sequences in TC-32 cells but not in a prostate cancer cell line. Since inhibition of t(11:22) gene product is correlated to effects on cell viability reduction of the fusion protein may thus offer insight into the biology of EFT.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0167-594X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
31
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
9-16
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:9049825-Bone Neoplasms,
pubmed-meshheading:9049825-Cell Division,
pubmed-meshheading:9049825-Cell Survival,
pubmed-meshheading:9049825-Electroporation,
pubmed-meshheading:9049825-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:9049825-Genetic Testing,
pubmed-meshheading:9049825-Humans,
pubmed-meshheading:9049825-Male,
pubmed-meshheading:9049825-Oligonucleotides, Antisense,
pubmed-meshheading:9049825-Prostatic Neoplasms,
pubmed-meshheading:9049825-Recombinant Fusion Proteins,
pubmed-meshheading:9049825-Sarcoma, Ewing,
pubmed-meshheading:9049825-Transcription, Genetic,
pubmed-meshheading:9049825-Translocation, Genetic,
pubmed-meshheading:9049825-Tumor Cells, Cultured
|
pubmed:year |
1997
|
pubmed:articleTitle |
Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides.
|
pubmed:affiliation |
Pediatric Branch, National Cancer Institute, Bethesda, MD 20892, USA.
|
pubmed:publicationType |
Journal Article
|